Covance Press Release

CHANDLER, AZ - Covance (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, opened its 288,000-square-foot facility in Chandler, Arizona last year. This new facility provides state-of-the-art preclinical safety testing services, including GLP toxicology and bioanalytical services.

Recently, Covance announced that the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) awarded full accreditation to the company's Chandler facility. AAALAC International endorses the ethical use of animals to advance medicine and science when alternatives are not available. Voluntary accreditation and assessment is designed to recognize research programs that demonstrate excellence in animal care and use.

"We are pleased to receive unanimous approval from AAALAC International for full accreditation with no additional recommendations for improvement," said Monique Heiser-Wong, vice president and general manager, Covance. "The Council on Accreditation of AAALAC International commended the management and staff at the Chandler facility for providing institutional and administrative commitment to the animal care program as evidenced by our newest facility, equipment, and programs."

"Covance is proud to increase its global footprint in North America and to now offer premium early drug development services at a West Coast facility," said Mike Lehmann, president, non-clinical safety assessment services, Covance. "AAALAC accreditation demonstrates Covance's commitment to deliver the highest levels of quality to our global clients - in both data quality and animal care."

Covance offers a complete range of toxicology services and safety assessment services, including standard and specialized services, to help pharmaceutical and biotechnology companies achieve study goals quickly and with greater confidence. Visit www.Covance.com to learn more.